About us

We are a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. Our mission is to bring transformational medicines to patients through innovation.

We see vast commercial opportunities for immuno-oncology and autoimmune biologics therapies in China and rest of the world. We were founded to capture the opportunities presented by the confluence of two major developments: the emergence of an attractive and growing biologics market in China, and revolutionary scientific breakthroughs in cancer and autoimmune disease medicines. 

To achieve our mission and capitalize on these commercial opportunities, we have developed a business model built on two pillars. The first is a fast-to-market China approach, and the second a fast-to-PoC (proof of concept) global approach. Reflecting these two approaches, we have established a China Portfolio and a Global Portfolio of novel or highly differentiated clinical and preclinical assets in the most exciting therapeutic areas of immuno-oncology and immuno-inflammation. Through our internal research and development efforts, and in-licensing arrangements with global pharmaceutical and biotech companies, we have built an innovative pipeline of more than ten assets in clinical and preclinical stages of development. We are currently running three Phase 1 clinical trials in the US and China, and a further four trials, mostly Phase 2 or 3, in China. 

We believe we are uniquely positioned as a China-based global player, with a presence in Shanghai, Beijing and the US, to tap into these vast commercial opportunities. Since its founding in 2016, I-Mab has rapidly become one of the top innovative biotech companies in China, and we have successfully raised more than US$400 million in equity financing from our dedicated group of investors, including leading healthcare-focused funds.  Our research and development capabilities encompass discovery, translational medicine, chemistry, manufacturing and controls (CMC) for biologics, pre-clinical development and clinical development, as well as business development functions. These integrated capabilities are strengthened by our deep understanding of China’s biologics regulatory framework combined with our direct access to extensive preclinical and clinical trial resources in China. I-Mab is now at a critical juncture to transition from a clinical-stage biotech company into a fully integrated end-to-end global biopharmaceutical company in the next few years.

Significant Progress

Our Vision

I-Mab’s competitive pipeline and dynamic business strategy makes it perfectly positioned to capitalize on unique business conditions in China: a growing talent pool of professionals with both global and local R&D expertise; a critical mass of CRO services operating according to global standards; a rapidly improving regulatory and drug-innovation environment; and large capital resources. These factors, coupled with the huge market potential of China’s vast patient population and growing global reach, give us remarkable power and speed in developing innovative medicines.

Important Events

Scroll to Learn More

Organization & Management Team

A core strength of I-Mab is our management team, which brings together decades of collective experience in drug discovery and development, for both global and Chinese markets. The expertise of our management, who are among the top talent in their respective fields, covers all aspects of R&D from candidate discovery and chemistry, manufacturing and controls (CMC) to clinical development and regulatory approval.

Founder and Chairman: Jingwu Zang, MD, PhD Founder and Chairman
Jingwu Zang, MD, PhD
I-Mab has built a globally competitive pipeline and a highly experienced team. We are passionate to develop transformational medicines to improve patients’ lives.

Jingwu Zang, MD, PhD

Founder and Chairman

Dr. Zang founded I-Mab in 2016 and he is currently I-Mab’s chairman and director. Under his leadership, I-Mab has built an innovative and globally competitive pipeline in only four years, and has evolved from an early-stage discovery company into a clinical stage company listed on the Nasdaq. 

Prior to founding I-Mab, Dr. Zang held the senior executive in global pharma and China pharma roles of chief scientific officer with Simcere Pharmaceuticals, president with BioSciKin, and senior vice president and head of R&D Center China with GlaxoSmithKline. 

In his career in China since 2002, Dr. Zang founded the Institute of Health Sciences in Chinese Academy of Sciences and co-founded the Institute Pasteur Shanghai, an independent non-profit life science institute to address public health problems in China. Dr. Zang also served as Dean of School of Medical Sciences at the Shanghai JiaoTong University and Director of Shanghai Institute of Immunology. Dr. Zang has published more than 160 scientific articles in prestigious journals, chapters, and books.

Dr. Zang received his medical degree from Shanghai JiaoTong University School of Medicine and Ph.D. in Immunology from University of Brussels. He completed his postdoctoral training at Harvard Medical School. At Baylor College of Medicine in Texas, Dr. Zang was a licensed physician by Texas Medical Board and Professor of Neurology and Immunology and Research Director of Multiple Sclerosis Center. 

Research and Development

Joan Huaqiong Shen

MD, PhD.


R&D is led by Joan Huaqiong Shen, MD, PhD, CEO of I-Mab.  Dr. Shen is a US board-certified physician and holds a PhD in life sciences from Indiana University School of Medicine, where she was appointed as an adjunct professor in the department of psychiatry. She also completed fellowships in endocrinology, psychopharmacology and clinical pharmacology. Her scientific contributions have led to multiple research grant awards and more than 30 publications.

Dr. Shen’s pharmaceutical career began at Eli Lilly & Company, after which she held executive positions at Wyeth, Pfizer, Jiangsu Hengrui Medicine and Johnson & Johnson. She was the clinical head at Pfizer China and the Chief Medical Officer at Jiangsu Hengrui Medicine, where she built the largest clinical team among Chinese domestic pharma companies and established successful clinical trials in China, the US and Australia. At J&J, Dr. Shen served as China Development Head and oversaw all clinical development programs in China, including multiple innovative drugs that were approved by China NMPA, such as Sirturo, Olysio, Imbruvica, Simponi, and Stelara.

Dr. Shen serves as co-chair of the R&D-based Pharmaceutical Association in China’s (RDPAC) core R&D team, sits on the China New Drug Research Evaluation Executive Committee, and is currently a guest professor at the Beijing University Clinical Research Institute.

Chemistry, Manufacturing and Controls (CMC)

Zheru Zhang


President, Head of CMC & Manufacturing

The CMC group is headed by Zheru Zhang, PhD, President, Head of CMC and Manufacturing.  Dr.Zhang obtained his PhD in biochemistry from the University of Alberta, Canada, and has more than 20 years of experience in CMC development and quality management in the pharmaceutical industry in the US, Korea and China. Dr. Zhang has extensive experience working with various regulatory authorities, including NMPA, FDA, EMA, MFDS, PMDA and TGA, on the development of biological products. Before joining I-Mab, Dr. Zhang held technical and management positions at Bristol-Myers Squibb and Johnson & Johnson, and also served as Vice President of Celltrion and President of Tasgen. During his pharma tenure, Dr. Zhang led or participated in Investigational New Drug applications for twenty biologics, and six global Biologics License Applications, including for the first biosimilar monoclonal antibody product approved in Europe, Japan and the US. Under the leadership of Dr. Zhang, the CMC organization is structured to include the following: process development function is led by Dr. Junhua Qiao; analytical development function is led by Dr. Xiangping Zhu; project management teams for China and Global portfolios are led by Dr. Charlie Zhang, Dr. Junhua Qiao and Dr. Sheng Yin; quality assurance function is led by Mr. Jack Qin.

I-Mab U.S.

Neil K. Warma, MBA

General Manager

I-Mab Biopharma USA, Limited

Neil Warma has been a successful healthcare entrepreneur for more than 25 years, having founded, managed and advised numerous biotech and pharmaceutical companies. Previously, as President and CEO of Opexa Therapeutics (NASDAQ: OPXA), a publicly traded biopharmaceutical company, Mr. Warma led the rebuilding of the company’s cell therapy platform and oversaw its advance through clinical development in autoimmune and orphan diseases. Prior to Opexa, he was CEO of Viron Therapeutics, a private biotechnology company developing novel protein-based therapeutics for cardiovascular disease and transplantation.

Mr. Warma spent several years in key management roles at Novartis Pharmaceuticals at its corporate headquarters in Basel, Switzerland, including time as Head of Global Pharma Policy and Advocacy, as well as in Global Marketing. Mr. Warma also founded and later sold MedExact, a company dedicated to providing clinical and treatment information to physicians and pharmaceutical companies over the Internet. As President, he oversaw the expansion of the operations in the US, Canada and France and its sale to a large European public company.

Mr. Warma obtained an honors degree in neuroscience from the University of Toronto and an International MBA from the Schulich School of Business at York University in Toronto.

Mr. Warma is responsible for leading the global expansion of I-Mab, with a focus on expanding the US business and building up I-Mab’s translational medicine group in the US, as well as further R&D and operational functions.


Jielun Zhu


Chief Financial Officer

As the Chief Financial Officer, Jielun Zhu, MBA, CFA, is in charge of the overall financial strategy and management, capital investment, corporate finance and investor relations. He is a veteran and expert in the finance industry, with over 11 years of experience in investment banking. From December 2015 to July 2018, prior to joining I-Mab, he served as a managing director and Asia Head of Healthcare Investment Banking and Capital Markets in Hong Kong for Jefferies Group LLC, a global full-service investment bank with a strong focus in healthcare.

At Jefferies, Mr. Zhu advised many biotechnology and healthcare clients globally on IPOs and other financings, as well as mergers and acquisitions. From August 2008 to September 2015, he worked for the Deutsche Bank Group in its Hong Kong office, occupying a succession of positions culminating in Director in the Corporate Finance Division, which entailed working with leading clients in the healthcare and other sectors in Greater China. From July 2007 to July 2008, he was an investment banker in Hong Kong with UBS AG. Before investment banking, Mr. Zhu was a strategy consultant in Boston focused on serving clients in the US pharmaceutical and biotechnology industry.

Mr. Zhu earned his MBA from Harvard Business School with distinction in June 2007 and his Bachelor of Arts degree with honors in mathematics-economics from Wesleyan University. He is also a Chartered Financial Analyst (CFA) charterholder.

Corporate Communications

Gigi Feng

Chief Communications Officer

The Corporate Communications team is led by Gigi, who oversees all communications across I-Mab, partnering with the executive team to communicate the Company's strategic narrative, R&D innovation, external collaborations and more.

Prior to joining I-Mab, Gigi served as Amgen’s Japan Asia Pacific regional head of Corporate Affairs, where she led communications efforts including executive communications, media relations, employee engagement, crisis communications and philanthropy to build the Amgen brand across 14 markets in the Asia Pacific region. Before joining Amgen, Feng held a series of communications leadership roles at Sanofi, where she positioned the company as a scientific partner of choice. Gigi also led the strategic communications group at an international communications and public affairs consultancy in Shanghai with a focus on the healthcare and consumer sectors.

Gigi is a graduate of Cornell University with a B.A. in Government and Asian Studies. She also completed an executive education program in business strategy at the Harvard Business School.

Global Business and Corporate Development

Weimin Tang


Executive Vice President of Global Business

The Global Business Development team and the Corporate Development team work closely to support I-Mab’s vision of becoming a fully integrated innovative biopharmaceutical company.

The Global Business Development team is led by Weimin Tang, PhD, who is responsible for the company’s overall business development strategy. Dr. Tang has a strong track record of successful global pharmaceutical business development. During his 15-year tenure in pharma business development, he worked at Pfizer, Bristol-Myers Squibb, Sanofi, and Johnson & Johnson. He also was Acting CEO of Hengrui Therapeutics, a US branch of Hengrui Pharmaceuticals. With broad experience in global and China marketplaces, the Business Development team works closely with other units within I-Mab to identify external partnering opportunities and a competitive pipeline. I-Mab remains actively engaged in in-licensing and out-licensing activities.

Raven Lin


Vice President of Corporate Development

Corporate Development is led by Raven Lin, PhD. His team provides long-term corporate development strategic direction, which covers global partnerships, alliance management, manufacturing capability and commercialization. The team is also focused on building an enterprise ecosystem that meets the company’s long-term business goals and financial strategies. Dr. Lin is an experienced business development executive with a strong track record in the pharmaceutical industry. He has a wealth of experience in licensing and mergers and acquisition, project management, and marketing and sales from positions he held at Mycenax and SynCore Bio. He has successfully completed several business development and partnership deals at I-Mab.

Company Operations

Min Yin

Vice President, Operations

The operations function includes Information Technology, Procurement, Government Affairs, Facilities and General Administration.  The team is managed by Ms. Min Yin, who has extensive experience in the Life Science industry with various roles covering finance, operations, commercial, internal control/audit and compliance.  Her previous employment included Smith & Nephew, SciClone Pharmaceuticals, Novartis Oncology and Boston Scientific.  She received her MBA from Rutgers, the University of New Jersey and her accounting degree from University of Nebraska.  She is a member of AICPA. 


Yifei Zhu

Chief Commercial Officer

The Commercialization team is led by Yifei Zhu, who is responsible for building and developing I-Mab’s commercialization infrastructure and strategies, and preparing for upcoming product launches.

Mr. Zhu has more than 20 years of successful commercialization experience at global and domestic pharma and biotech companies. Prior to joining I-Mab, he served as Vice President and General Manager of the sales division of Qilu Pharmaceutical Group where he managed the company’s sales and marketing team. During his tenure at Qilu, he successfully led the launch of the first domestic biosimilar product of bevacizumab. Mr. Zhu has also served as the Chief Commercial Officer of BeiGene where he played an instrumental role in the expansion of BeiGene's commercialization team and the implementation of its commercialization strategies.

Mr. Zhu also worked for Xi'an Janssen for more than 20 years where he held various senior management positions. During this period, he built and managed numerous business units, covering a wide range of therapeutic areas including oncology, immunotherapy, skin diseases, infectious diseases and the central nervous system.


Scientific Advisory Board



Patricia LoRusso, DO, MA, PhD

Current Academic Appointments:Professor of Medicine and Associate Director of Innovative Medicine and Director of Early Therapeutics Disease-Aligned Team at Yale Cancer Center.

A Member of the NCI Board of Scientific Council.

R&D Highlights:Dr. LoRusso heads the early clinical trials program at Yale Cancer Center and has been Principal Investigator of the National Cancer Institute Phase 1/early phase clinical trials program grant for more than 20 years, and is currently primary investigator or co-investigator on numerous clinical trials.

Eric K. Rowinsky, MD

Current Academic Appointment:Adjunct Professor of Medicine at New York University School of Medicine.

Industry Experience:Advisor to C-Bridge Capital, US Chief Medical Officer for Everest Medicines, Inc.

R&D Highlights:At ImClone Systems (now a wholly owned subsidiary of Eli Lilly), Dr. Rowinsky and his team developed and registered cetuximab (Erbitux) and ramucirumab in five indications and two other monoclonal antibodies.

Howard L. Weiner, MD

Current Academic Appointment:Robert L. Kroc Professor of Neurology at the Harvard Medical School; Director of the Partners Multiple Sclerosis Center; Co-Director of the Ann Romney Center for Neurologic Diseases at Brigham & Women's Hospital in Boston

R&D Highlights:Dr. Weiner pioneered immunotherapy in multiple sclerosis (MS) and has investigated immune mechanisms in nervous system diseases including MS, Alzheimer's disease, amyotrophic lateral sclerosis, stroke and brain tumors.

Yilong Wu, MD

Current Academic Appointment:Professor of Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences and Guangdong Lung Cancer Institute; lifetime Director and former Vice President of Guangdong General Hospital (GGH); and Member of Board of Directors of the International Association Study of Lung Cancer (IASLC).

Winner of Outstanding Science Achievement from IASLC (IASLC Paul A. Bunn, Jr. MD Scientific Award).

R&D Highlights:Prof. Wu is a pioneer of lung cancer research in China, gaining tremendous recognition from peers all over the world. He has committed himself to battling thoracic oncology at the front line.

Timothy A Yap, MD, PhD

Current Academic Appointment:Associate Professor of Department of Investigational Cancer Therapeutics (Phase 1 Program) and the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center; Associate Director of Translational Research in the Institute for Personalized Cancer Therapy.

Industry Experience:Medical Director of the Institute for Applied Cancer Science.

R&D Highlights:Dr. Yap’s main research focuses on first-in-human and combinatorial development of molecularly targeted agents and immunotherapies, and their acceleration through clinical studies using novel predictive and pharmacodynamics biomarkers.

Roy S. Herbst, MD, PhD

Current Academic Appointments:Ensign Professor of Medicine (Medical Oncology), Professor of Pharmacology, and Chief of Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital; and Associate Cancer Center Director for Translational Research at Yale Cancer Center.

R&D Highlights: Dr. Herbst is nationally recognized for his leadership and expertise in lung cancer treatment and research. He has led the Phase 1 development of several of the new generation of targeted agents for non-small cell lung cancer (NSCLC) and participated in the registration of pembrolizumab for the treatment of advanced NSCLC.

Chen Dong, Ph.D.

Current Academic Appointments:Professor and Director of the Institute for Immunology at Tsinghua University; Fellow of the American Association for the advancement of Science; Member of the Chinese Academy of Sciences.

Winner of 2009 American Association of Immunologists-BD Bioscience Investigator Award and 2019 International Cytokine and Interferon Society Biolegend-William E. Paul Award.

Editor for Immunity; Editor-in-chief for Frontiers in Immunology- T Cell Biology and Associate Editor for China Sciences- Life Sciences.

R&D Highlights: Dr. Dong’s research is to understand the molecular mechanisms whereby immune and inflammatory responses are normally regulated, and to apply this knowledge to the understanding and treatment of autoimmunity and allergy disorders as well as cancer. The work from Dr. Dong’s group has led to the discoveries of Th17 and T follicular helper (Tfh) cell subsets in the immune system and elucidation of their biological and pathological functions. Dr. Dong has over 200 publications and was rated highly cited researcher for seven years from 2014 to 2020.

Jun MA,M.D.

Current Academic Appointments:Director of the Harbin Institute of Hematology & Oncology, and Chief Supervisor of Supervisory Committee at the Chinese Society of Clinical Oncology.

R&D Highlights: He started his studies in the University of Tokyo Hospital and, over the decades, his research focused on treatments for leukemia and lymphoma. He was the first to establish a culture system for multiple hematopoietic progenitor cells in vitro in China. Since 1983, he has used sequential therapy of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) to treat acute promyelocytic leukemia (APL) for about 1200 cases. Dr. Ma has published about 200 articles and conducted 8 China’s National R&D Programs and 25 provincial or municipal-level projects.



TigerMed and BioSciKin were early investors when Third Venture Biopharma was first founded in 2015. Series A financing of Third Venture was led by I-Bridge Capital in 2016. In 2017, Third Venture Biopharma merged with Tasgen to become I-Mab Biopharma and subsequently completed the Series B financing of US$120 million. The Series B round was led by C-Bridge Capital, with Tasly and Genexine participating. The Series C round of US$200 million was completed in June 2018 and was led by Hony Capital, along with Hillhouse Capital, HOPU Investments, CDH Investment, Ally Bridge Group, Singapore-based EDB, and existing investors C-Bridge Capital and Tasly Capital. The proceeds of the financing are being primarily used to advance the preclinical and clinical development of the company’s core products and major pipeline assets with best-in-class and first-in-class potential.

About Hangzhou Tigermed Consulting

Hangzhou Tigermed Consulting Co., Ltd (SHE:300347) is a leading Contract Research Organization (CRO) in China dedicated to providing professional full clinical-trial services. Since its inception in 2004, Tigermed has been committed to accelerating medical product development while maintaining cost efficiency and quality.

Headquartered in Hangzhou, Tigermed operates 33 subsidiaries, 63 offices across China and 12 overseas offices in Hong Kong China, Taiwan China, the US, Switzerland, Canada, Korea, Australia, Japan, Malaysia, Singapore, India and Romania, with over 3,600 full-time staff. Tigermed has serviced more than 600 local and global clients in the conduct of more than 1,060 clinical trials. Tigermed is recognized as “The Innovative Clinical CRO” in China, owning to our involvement in the development of more than 150 innovative drugs.

More information

About Genexine Inc.

Genexine, Inc., listed on KOSDAQ (095700) since 2009, is a clinical-stage biotherapeutics company focused on the development and commercialization of therapies in immuno-oncology and orphan diseases. Genexine has a robust pipeline, with assets in clinical and preclinical stages based on long-acting Fc fusion technology and therapeutic DNA technology.

Founded in 1999, Genexine has more than 140 employees, including 70 scientists with MSc or PhD degree. Genexine is located in Pangyo Techno Valley near Seoul, Korea, with a branch office in New York, USA.

More information

AnLong Medical Fund

AnLong Medical Fund is a VC fund, which is based in China, managed by professionals in the field of life sciences and health care, focusing on innovative bio-pharmaceuticals and medical devices. The management team has scientific research, multinational companies, entrepreneurship and investment experience. With a strong professional background of life sciences and health care, this team is the perfect combination of returnee and local experience. AnLong always focus on early stage of projects and start-ups, and has invested in Innovant, Third Venture, Laekna, and Connect Pharma, which are leading players in Chinese bio-pharmaceuticals industry.

More information

About Simcere Pharmaceutical Group

Simcere is an R&D -driven Chinese pharmaceutical company committed to bringing high-quality and more effective therapies to patients by combining in-house R&D with partnerships. Simcere focuses its efforts on the therapeutic areas of oncology, neurology, inflammation/immunology, cardiovascular and infectious diseases.

Simcere is dedicated to R&D of innovative pharmaceuticals and branded generic drugs in China, with a State Key Lab of Translational Medicine and Innovative Drug Development. Simcere’s commercial capability is demonstrated by the fact that all the top products of the company have a leading market share in China.

By leveraging partnering experience with multinational pharmaceutical companies and innovative biotech companies, Simcere continues to push the boundaries of medical science and create value for partners in China.

More information

About China Renaissance Group

China Renaissance Group is a leading financial institution that combines advisory services for private placements, mergers and acquisitions, securities underwriting, research, sales and trading, investment management and other financial services. Providing one-stop financial services across mainland China, Hong Kong and the US, CR Group operates a competitive and unique international network that connects China’s capital markets with the rest of the world, serving new entrepreneurs and investors globally.

More information

About the Economic Development Board

The Economic Development Board, a government agency under Singapore’s Ministry of Trade and Industry, is responsible for strategies that enhance Singapore’s position as a global center for business, innovation, and talent.

More information

About Lake Bleu Capital (formally Ally Bridge Group)

Lake Bleu Capital, originally Ally Bridge Group (ABG), is a global healthcare-focused investment group founded by Frank Yu. Mr. Yu and his team began investing in healthcare in China in 2011, and have since evolved into successful, global healthcare investors. Today, Lake Bleu and its affiliates manage close to US$2 billion in assets and a portfolio of some of the world’s most novel life sciences companies and technologies in the US, Europe and China.

More information

About C-Bridge Capital

C-Bridge Capital is a healthcare-dedicated private equity firm, focused on growth and late-stage investment opportunities. C-Bridge Capital's current portfolio includes China's leading players in pharmaceuticals, medical devices, diagnostics and healthcare services. C-Bridge Capital currently manages more than US$700 million in assets. With the power of capital markets, C-Bridge Capital is committed to supporting commercialization of cutting-edge technologies and companies that fulfil unmet medical needs to improve the standard and quality of patient care.

More information

About Tasly Group

With more than 20 years of history, Tasly Group is one of the biggest pharmaceutical companies in China. Its business focuses on R&D, manufacturing and sales of modern traditional Chinese medicines, biologics and small molecules covering all the major therapeutic areas. Tasly’s products are registered in more than 34 countries across the globe, and it owns one of the largest marketing and sales teams in China.

More information

About Hony Capital

Founded in 2003 and sponsored by Legend Holdings, Hony Capital specializes in buyout investments. It currently has US$10 billion under management and includes investors from China and the world’s leading investment institutions. Hony Capital is committed to financial innovation, helping Chinese enterprises go global and foreign enterprises to enter China. Since 2014, Hony Capital has established Hospital Corporation of China and Best Food Holding as its investment and operational management platforms to tap opportunities in healthcare and other industries.

More information

About Hillhouse Capital

Hillhouse Capital Group is a leading investment management firm. Founded by Lei Zhang in 2005, Hillhouse invests with a long-term time horizon, and independent proprietary research is key to its investment process. The team focuses on a number of sectors – consumer; technology, media, telecom; industrial; and healthcare – and invests in companies across all equity stages. Hillhouse manages capital for institutional clients such as university endowments, foundations, sovereign wealth funds, pensions and independent family-run institutions.

More information

About HOPU Investment

HOPU Investment is a leading private equity investment firm founded by Mr. Fang Fenglei in 2008. Hopu has more than US$12 billion of assets under management to date.

More information

About CDH Fund

Established in 2002, CDH Investments is one of the leading alternative investment fund managers focused on China today with more than US$17 billion of assets under management, as of December 31, 2017. CDH was founded by Wu Shangzhi, Jiao Shuge and four other investment professionals who worked together in the direct investment department of China International Capital Corporation.

More information

About Qianhai Fund of Funds LLP

The Qianhai Fund of Funds is a Limited Liability Partnership fund of funds set up in accordance with the Shenzhen Municipality’s plan to support the private investment ecosphere and favorable tax policies via the new Qianhai economic district. The central government of China State Council document, “Supporting Related Policies of Development and Opening in Shenzhen Qianhai, a Shenzhen and Hong Kong Modern Service Industry Cooperation District”, also supports a domestic fund of funds for venture capital and private equity.

The Qianhai Fund of Funds LLP (Qianhai FoF) established December 2015 has initial assets under management of RMB 28.5 billion. The successful founding of the Qianhai FoF marks the completion of the fourth of eight items for financial innovation as laid out by the State Council. The Qianhai FoF is of epoch-making significance as it pushes forward China’s private equity investment industry by introducing an accredited investors model to the industry and transforming the local private investment industry with the emergence of professional limited partners.

More information

About Rainbow Capital

Rainbow Capital, based in Hong Kong, is a single-family office of Mr. Jacky Xu, Founder and Chairman of Trendy International Group, a leading global conglomerate that delivers a range of fashion and lifestyle services. Mr. Xu is also an angel investor of VIPShop Holdings Limited and has served as a director of the company since 2011. Rainbow Capital manages the family’s transgenerational long-term capital over US$1 billion, focused on innovation-driven technology and healthcare sectors.

More information


US (Office)

Suite 710, 9801 Washingtonian Blvd, Gaithersburg, Maryland 20878, USA

Tel: +1 301-670-2800 ex 1990

Beijing (Office)

Rm 15A02,15A/F, Dacheng Plaza, 127 Xuanwumen West Street, Xicheng District, Beijing, China 100031

Tel: + 86-10-5617 7946

Shanghai (Headquarter)

Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District, Shanghai, China, 201210

Tel: +86-21-6057 8000

Hong Kong

Suite 5105, 51/F, The Center, 99 Queen’s Road Central, Hong Kong

Tel: +852 2816 1033

Copyright I-MAB Biopharma Co., Ltd. All rights reserved 2019 沪ICP备17007960号-2